[Recommendations from Experts in the Management of Adverse Reactions 
to ALK Inhibitors (2021 Version)]

Area of Science:

• Oncology
• Pharmacology
• Pulmonology

Background:

• Anaplastic lymphoma kinase (ALK) fusion genes are critical drivers in non-small cell lung cancer (NSCLC) development.
• Targeted therapy with ALK inhibitors (ALKi) is a primary treatment for ALK-positive NSCLC.
• Approved ALKi in China include crizotinib, ceritinib, alectinib, and ensartinib.

Purpose of the Study:

• To address the lack of clinical guidelines for managing adverse reactions to ALK inhibitors.
• To provide practical strategies for the clinical management of ALKi-induced adverse events.
• To standardize adverse reaction management for ALK-targeted therapies in NSCLC.

Main Methods:

• Development of expert recommendations for managing ALKi adverse reactions.
• Consensus-building led by the Lung Cancer Professional Committee of Sichuan Cancer Society and Sichuan Medical Quality Control Center for Tumor Diseases.
• Focus on practical and feasible strategies for clinical application.

Main Results:

• Publication of the 'Recommendations from experts in the management of adverse reactions to ALK inhibitors (2021 version)'.
• Establishment of a framework for managing adverse events associated with ALKi therapy.
• Guidance tailored for the Chinese clinical context.

Conclusions:

• The expert recommendations offer crucial guidance for the safe and effective use of ALKi in NSCLC patients.
• Standardized management of adverse reactions is essential for optimizing ALKi treatment outcomes.
• These recommendations aim to improve clinical practice and patient care in ALK-positive NSCLC.